Kornimate/medical-research-clean huggingface dataset:
impact of serum progesterone levels on the day of fresh and frozen embryo transfer on the ongoing pregnancy rates.

Conditions: Infertility

Summary: serum progesterone levels prepare the endometrium for implantation and play an important role during embryo transfer (et). in clinical practice, luteal phase support progesterone supplementation is systematically offered to all women undergoing medically assisted procreation (amp), independently of et conditions (fresh and frozen). the investigators propose to perform a prospective cross-sectional single-center cohort study to measure progesterone levels on the day of the et on all amp cycles and to compare these levels between active pregnancies and et unsuccessful cycles. they will determine progesterone threshold levels corresponding to successful attempts in all et strategies (fresh and frozen) as well as clinical and biological risk factors leading to luteal phase deficiency during et. they could therefore individualize progesterone supplementation according to patient's needs.


Eligibility criteria:
inclusion criteria: * age ≥ 18 years * planned embryo transfer * signed informed consent exclusion criteria: * patients falsely included, major inclusion criteria not respected * lack of social insurance * refusal to participate in the research

Keywords: serum progesterone embryo transfer pregnancy rate
observational study to evaluate health status of chronic obstructive pulmonary disease (copd) patients in response to real-life treatments in thailand

Conditions: Chronic Obstructive Pulmonary Disease

Summary: the purpose of this study is to evaluate health status of uncontrolled chronic obstructive pulmonary disease (copd) patients in response to treatments in clinical practice.

mc md

Eligibility criteria:
inclusion criteria: 1. provision of informed consent prior to any study specific procedures 2. male or non-pregnant female aged \>40 years 3. a clinical diagnosis of copd with fev1/ fvc \<0.70 and require combination or modified therapy 4. smoke \> 10 pack year exclusion criteria: 1. involvement in the planning and/or conduct of the study (applies to both astrazeneca staff and/or staff at the study site) 2. participation in a clinical study (precluding non-interventional study or registry) during the last 3 months

Keywords: copd and ccq score changes in pef,overall ccq score
safety and efficacy of nvxt solution in mild-to-moderate fungal infection of the toe nail

Conditions: Onychomycosis

Summary: this study will examine the safety, tolerability and efficacy of nvxt in a new formulation in patients with mild-to-moderate fungal infection of the toe nail.

this phase iia pilot multiple-dose study will examine the safety, tolerability and efficacy of nvxt in a new formulation in patients with mild-to-moderate fungal infection of the toe nail.

Eligibility criteria:
inclusion criteria: * clinically diagnosed onychomycosis * presence of dermatophyte fungal infection with no current topical or systemic antifungal therapy * clinical diagnosis of mild-to-moderate fungal infection of at least one toe involving 10-50% of the nail area, without involvement of one of the lunular proximal regions * positive potassium hydroxide mount preparation * positive fungal culture for a dermatophyte exclusion criteria: * nail or anatomical abnormalities of the toe that may interfere with evaluations or dosing compliance
acupuncture approaches for chronic pain

Conditions: Chronic Pain; Osteoarthritis; Neck Pain; Back Pain

Summary: chronic pain is a major public health problem that places many burdens on individuals, including impairment of physical and psychological functioning, lost productivity, and side effects of medications used to treat pain. there is also substantial evidence that minority populations differ both in prevalence and outcomes of chronic pain; access to care is a key component in these differences. strong evidence now supports the use of acupuncture in the treatment of chronic pain conditions, including when provided in the primary care setting to participants from ethnically diverse, medically underserved populations. acupuncture is slowly being integrated into pain management in many conventional health care settings, but cost and reimbursement for this service remain obstacles to offering acupuncture, especially in primary care and safety net settings. because group acupuncture can be offered at much lower cost, demonstrating that individual and group delivery are equally effective could reduce barriers to use of this effective pain management approach. the primary aim of this study will be to evaluate whether acupuncture delivered in the group setting for participants with chronic pain is equal to acupuncture delivered in the individual setting. a secondary objective will be to use qualitative analysis to understand and describe the participants' experience of both acupuncture approaches, and to utilize this data to inform intervention delivery and dissemination, to better incorporate the participants' perspective.


Eligibility criteria:
inclusion criteria: * referred by a primary care provider from one of our participating primary care health centers * provider-documented diagnosis of osteoarthritis (any joint), neck pain, or back pain * self-reported pain score of ≥4 for at least 3 months prior to program entry * able to provide consent for treatment and data collection in either english or spanish exclusion criteria: * \< 21 years of age * chronic pain not documented or self reported pain of ≥4 for less than 3 months. * currently taking oral or injectable anticoagulants. * lack of contact information or unavailable for duration of entire treatment period (24 weeks) * inability to consent to treatment and data collection. * active psychosis * active substance abuse

Keywords: acupuncture group/community acupuncture individual acupuncture chronic pain underserved urban primary care osteoarthritis back pain neck pain
evaluation of infrared thermal imaging in diagnosis of osahs in children

Conditions: Infrared-thermal-imaging

Summary: osahs is a common sleep breathing disorder in children, with the same incidence as childhood asthma, and is mainly caused by upper airway stenosis caused by tonsil/adenoid hyperplasia. clinical findings show that children with osahs often present rhinitis symptoms and like rubbing eyes, but there is no evidence to suggest a correlation. children with osahs suffer from recurrent hypoxemia during sleep, and the existing detection methods such as lateral nasopharyngeal radiographs and electronic nasopharyngoscopy can only reflect the structural and morphological changes of the oral, nasal and pharyngeal tissues, but cannot prove their functional status. previous studies have found that infrared thermal imaging can reflect the oral, nasal and pharyngeal inflammation of patients, and the infrared expression of patients' frontal region and eyes can also reflect the physiological changes caused by sleep deprivation.

in this project, the children were divided into four groups: primary snoring, critical osahs, mild osahs and moderate to severe osahs, and the tests were completed, including lateral nasopharyngeal radiographs, infrared detection of oropharynx and pharynx, infrared detection of frontal area and eye area, intelligence and behavior scale assessment, etc. furthermore, the correlation between infrared detection and obstructive sleep apnea hypopnea index, peripheral blood oxygen saturation, adenoid hyperplasia degree of nasopharyngeal lateral film as parameters were analyzed, and the sensitivity and specificity of infrared detection was determined to confirm the diagnostic value of osahs. it provides a theoretical basis for finding a convenient, non-damaging, non-radiation, visual and suitable for children functional image detection method.

Eligibility criteria:
inclusion criteria: * children ages 2 to 14 with sdb related symptoms exclusion criteria: * 1) congenital abnormalities of the nose and throat or airway; 2) craniofacial deformity 3) neuromuscular dysregulation 4) history of adenoids and/or tonsillectomy.
drug use investigation of effexor (secondary data collection study; safety and efficacy of effexor.under japanese medical practice)

Conditions: Depression/Depressed State

Summary: secondary data collection study; safety and efficacy of effexor.under japanese medical practice

this study will be conducted under the central registration system until the number of subjects who meet the conditions for registration reaches the target number of subjects. 12 weeks from the start date. the patients who completed the 12-week treatment with this product will be observed up until week 52.

Eligibility criteria:
inclusion criteria: * patients with no experience of using this product who will be administered this product for the first time exclusion criteria: * exclusion criteria are not provided in this study

Keywords: effexor depression depressed state
esketamine on postoperative sleep disturbance of patients undergoing spinal surgery

Conditions: Esketamine; Sleep Disturbance; Spinal Surgery

Summary: the goal of this clinical trial is to learn about the effect of intraoperative esketamine infusion on postoperative sleep disturbance(psd) of patients undergoing spinal surgery. the main aims to answer are: * to explore the effect of intraoperative infusion of esketamine on the incidence of postoperative sleep disturbance and sleep quality in patients undergoing spinal surgery. * to explore the effect of intraoperative infusion of esketamine on postoperative pain, anxiety and depression ; participants will be patients undergoing spinal surgery with general anesthesia at beijing tiantan hospital. 0.3mg/kg/h esketamine or saline will be infused during surgery . the incidence of sleep disturbance , sleep quality, pain scores, hospital anxiety and depression scores and perioperative adverse events after surgery will be investigated.


Eligibility criteria:
inclusion criteria: * 18-65 years old, * american society of anesthesiologist (asa) physical status classification i to iii ; * patients scheduled to undergo elective spinal surgery under general anesthesia; * signed informed consent ; exclusion criteria: * bmi \> 35kg / m2 ; * severe lesions of important organs and systems ; * the estimated duration of surgery is more than 4 hours * patients who were retained tracheal intubation or admitted to intensive care unit (icu) postoperatively. * history of adverse reactions or contraindications to ketamine and esketamine ; * cognitive dysfunction, communication disorders ; * refused to participate in this study.
impact of adalimumab (humira®) therapy on selected health care resource utilization and sick leave in patients with ankylosing spondylitis in clinical practice

Conditions: Ankylosing Spondylitis

Summary: the purpose of this study was to assess the proportion of as patients achieving treatment response to adalimumab therapy.

this post-marketing observational study (pmos) was performed in a multi-country, multi-center, single-arm format. data were collected prospectively and retrospectively. adult patients with diagnosis of as who were assigned for treatment with adalimumab (humira®) were eligible for participation. each patient included in this study was to be observed during his/her adalimumab treatment for a maximum of 12 month period. during this period four follow-up visits were planned for observation of the patient and documentation of data. ideally, these visits should have been performed approximately 3 (v1), 6 (v2), 9 (v3) and 12 (v4) months after the baseline visit (v0).

Eligibility criteria:
inclusion criteria: * had ankylosing spondylitis (as) and was eligible to start and/or continue adalimumab therapy according to the local product label and prescription guidelines, * had been started on adalimumab therapy no more than one (1) month prior to the study enrollment * had negative result of tuberculosis (tb) screening test or was receiving tuberculosis prophylaxis as per local guidelines * provided written authorization to the investigator to use and/or disclose personal and/or health data, or informed consent if requested by the local regulations exclusion criteria: - had contraindications for the treatment with adalimumab

Keywords: ankylosing spondylitis effectiveness post-marketing observational study (pmos) adalimumab humira®
the neuro zti cochlear implant system efficacy and safety in adults

Conditions: Hearing Loss, Sensorineural; Hearing Loss, Cochlear; Deafness

Summary: the purpose of the study is to assess the efficacy and the safety profile of the neuro cochlear implant system (cis) in adults with severe-to-profound hearing loss.

appropriate adult cochlear implant candidates with sensorineural hearing loss, from english french canadian centres and danish centre, received neuro zti cochlear implant and fit with neuro one sound processor. speech perception testing, using hint (hearing in noise test) sentences in quiet (65 db spl) (decibel, sound pressure level) and in noise (+10 db snr) (decibel, signal-to-noise-ratio), will be administrated pre-operatively in the best listening conditions and 3, 6, and 12 months post-activation in the implanted ear. adverse events will be collected during the surgery and over the post-surgical period from activation to12 months post-activation. safety will be assessed on the overall english, french and danish participants. efficacy will be assessed on english speaking participants.

Eligibility criteria:
inclusion criteria * adults, eighteen (18) years of age or older. * bilateral severe-to-profound sensorineural hearing loss, defined by pure-tone average (pta) ≥70 db hl (hearing level) at 500, 1000 and 2000 hz on both ears. * hint sentences recognition scores in quiet ≤ 50% correct, in the best-aided listening condition. * post-lingual onset of deafness. * primary implantation (no re-implantation). * up-to-date pneumococcal vaccine. exclusion criteria * medical conditions that contraindicate undergoing cochlear implant surgery (middle ear diseases i.e. aom/csom (acute otitis media/chronic suppurative otitis media) , lesions of auditory nerve, pathologies of central auditory pathway, otosclerosis; cochlear malformation i.e. mondini malformation, cochlear ossification, large vestibular aqueduct). * unrealistic expectations regarding the possible benefits, risks, and limitations that are inherent to the surgical procedure and medical device. * unwillingness or inability of the candidate to comply with all investigational requirements.

Keywords: hearing loss cochlear implant surgery otorhinolaryngology oticon medical neuro cochlear implant system
post marketing surveillance on long-term use with norditropin® (short stature due to noonan syndrome)

Conditions: Genetic Disorder; Noonan Syndrome

Summary: the purpose of this study is to collect information about safety and effectiveness for long term use of norditropin®. participants will attend the medical institution according to usual practice and receive medical care, as agreed with the study doctor.


Eligibility criteria:
inclusion criteria: * signed informed consent obtained before any study-related activities (study-related activities are any procedure related to recording of data according to the protocol). * the decision to initiate treatment with commercially available norditropin® has been made by the patient/legally acceptable representative (lar) and the treating physician before and independently from the decision to include the patient in this study. * for non-naïve patients; patients who were previously enrolled in study: ghliquid-4020. * for naïve patients; short stature due to noonan syndrome diagnosed by the physician and a decision to initiate treatment with norditropin® has been made by the patient/parent and the physician. at study sites, all patients will be registered consecutively from the first patient after approval date (consecutively registered system). * male or female, 3 years old or over, bone age: less than 17 years old for male / less than 15 years old for female. exclusion criteria: * previous participation in this study. participation is defined as having given informed consent in this study. * known or suspected allergy to study products or related products. * in case of naïve patients, patients who have received growth hormone (gh) products for treatment of indication other than short stature due to noonan syndrome before approval date of noonan indication.
pediatric intubation with difficult airway

Conditions: Trauma; Intubation, Endotracheal

Summary: the aim of this study was to compare time, success rates of different video laryngoscopes for the emergency intubation with an immobilized cervical spine in a standardized pediatric manikin model.


Eligibility criteria:
inclusion criteria: * give voluntary consent to participate in the study * minimum 1 year of work experience in emergency medicine * experienced emergency medical personnel (physicians, nurses, paramedics) exclusion criteria: * not meet the above criteria * wrist or low back diseases
enteral granulocyte colony stimulating factor and erythropoietin early in life increases feeding tolerance in preterm infants: a randomized controlled trial

Conditions: Feeding Intolerance; Necrotizing Enterocolitis

Summary: with preterm birth, the ingestion of amniotic fluid containing enterocyte trophic factors ceases abruptly. this likely predisposes them to villous atrophy feeding intolerance and necrotizing enterocolitis(nec) once feedings are instituted.granulocyte colony-stimulating factor (g-csf) and erythropoietin (epo) have important non-hematopoietic roles in human developmental biology. among these roles, they have trophic actions on villous height and bowel length of the developing intestine.the aim of this study is to evaluate the efficacy of enteral recombinant human g-csf and recombinant human epo in prevention of feeding intolerance and /or nec in preterm infants.


Eligibility criteria:
inclusion criteria: * premature neonates \< 33 weeks gestational age exclusion criteria: * major congenital anomalies * prior use of cytokines

Keywords: feeding intolerance recombinant growth factors g-csf epo necrotizing enterocolitis
study of the wallflex™ biliary partially-covered stent for the palliative treatment of malignant bile duct obstruction

Conditions: Biliary Strictures Caused by Malignant Neoplasms

Summary: this is a a prospective study of the wallflex™ biliary partially-covered stent designed to collect data to support regulatory clearance by the fda in the united states and to determine the functionality of the wallflex™ biliary partially covered stent as a palliative treatment for malignant bile duct obstruction.


Eligibility criteria:
inclusion criteria: * age 18 years or older * inoperable extrahepatic biliary obstruction by any malignant process * indicated for metal stent placement for palliative treatment of biliary stricture(s) produced by malignant neoplasms * willing and able to comply with the study procedures and provide written informed consent to participate in the study exclusion criteria: * participation in another invesitgational study within 90 days prior to date of patient consent. * strictures that cannot be dialated enough to pass the delivery system * perforation of any duct within the biliary tree * presence of any esophageal or duodenal stent * patients for whom endoscopic procedures are contraindicated * patients with known senesitivity to any components of the stent or delivery system * patients with active hepatitis

Keywords: biliary strictures malignant neoplasm palliation
the study of irinotecan plus epirubicin as the second-line chemoregime for advanced gastric cancer

Conditions: Stage IV Gastric Cancer With Metastasis

Summary: this study is to determine the response rate and safety profile of irinotecan plus epirubicin as the second-line chemotherapy for advanced gastric cancer and fully evaluate the feasibility and effectiveness of the regime.

the main purposes: to determine the progression-free survival (pfs) and overall survival (os) of gastric cancer patients given irinotecan + epirubicin as second-line treatment, who are at stage iv with disease progressed or recurred after first-line chemotherapy failed, , the secondary purposes: to determine disease control rate (disease control rate, dcr), the objective response rate (object response rate, orr) and the quality of life (quality of life, qol)

Eligibility criteria:
inclusion criteria: * aged between 18 to 70 years * the pathologically confirmed gastric adenocarcinoma and the failure of first-line chemotherapy * measurable lesions outside the stomach * ecog(eastern cooperative oncology group ) score between 0 to 1 * expected survival time of at least 3 months * subjects receiving treatment for other damage caused has been restored, which it accepted the nitroso or mitomycin interval\> 6 weeks, the acceptance of other cytotoxic drugs, radiotherapy or surgery\> = 4 weeks, and the wound has completely healed. no bleeding, no nervous system transferred * blood and organ function was normal exclusion criteria: * comorbid with other malignant tumors * pregnant and lactating women * with the disease of endangering patient's safety and affecting the completion of the study * patients suffering from high blood pressure by antihypertensive treatment cannot control (systolic blood pressure\> 140mmhg, diastolic blood pressure\> 90mmhg,) there is more than class i and class i arrhythmia coronary heart disease, with more than class i heart dysfunction * major organ failure, such as decompensated heart and lung failure, liver failure, renal failure and patients with intestinal obstruction ipate in other clinical trials of patients in the past four weeks * participated in clinical trials with other drugs or using other drugs during past 4 weeks * lesions which can't be measured such as pleural effusion, ascites, peritoneal cancer lesions, diffuse liver and bone metastases violation, brain metastasis

Keywords: second line chemoregime gastric cancer
association between framingham risk score, hscrp and vascular inflammation: analysis with 18f-fluorodeoxyglucose positron emission tomography

Conditions: Cardiovascular Risk

Summary: framingham risk score is well known screening tool that detect cardiovascular (cv) risk. but it is not suitable for cv risk in mild risk group. so 18f-fluorodeoxyglucose positron emission tomography (fdg-pet) is a new imaging technique for detecting vascular inflammation within atherosclerotic plaques and hscrp is also arising detection tool of cv risk. the investigators are examining this association in normal and impaired glucose tolerance patients groups.

we examined vascular inflammation using fdg-pet scan in 178 subjects (normal and impaired glucose tolerance groups). vascular 18f-fdg uptake was measured as both the mean and maximum blood-normalized standardized uptake value (suv), known as the target-to-background ratio (tbr). and we analyzed that the association with framingham risk score, hs crp and vascular inflammation by fdg-pet scan.

Eligibility criteria:
inclusion criteria: * healthy subjects exclusion criteria: * a history of cardiovascular disease (myocardial infarction, unstable angina, stroke or cardiovascular revascularization) * active inflammatory disease, recent active infection * stage 2 hypertension (resting blood pressure, ≥ 160/100 mmhg) * diabetes mellitus * systemic disorders such as severe hepatic, renal, and hematologic diseases * taking drugs known to interfere with vascular inflammation measured by fdg-pet.

Keywords: atherosclerosis inflammation hscrp framingham risk score positron emission tomography inflammation in fdg-pet